Payment overview · 2025
General Payments
$221.64
6 reported records · 4 companies
Healthcare provider profile · identity verified
Douglas D Stern, DO
Allopathic & Osteopathic Physicians|General Practice · MC CONNELLSBURG, PA · NPI 1023065968
Verified facts
What the public records show
CMS Open Payments records show Douglas D Stern, DO received $221.64 in general payments during 2025 across 6 reported records.
Novo Nordisk Inc accounted for 70.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $155.83 | 70.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.32 | 14.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.32 | 8.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.17 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $221.64 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $132.62 | 2 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $32.32 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $15.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 168 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 157 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
81 | 26 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
168 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
157 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 798 | 185 |
| Atorvastatin Calcium | Atorvastatin Calcium | 792 | 165 |
| Pantoprazole Sodium | Pantoprazole Sodium | 736 | 156 |
| Metformin Hcl | Metformin Hcl | 566 | 122 |
| Lisinopril | Lisinopril | 557 | 136 |
| Gabapentin | Gabapentin | 521 | 114 |
| Omeprazole | Omeprazole | 455 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 441 | 118 |
| Losartan Potassium | Losartan Potassium | 414 | 95 |
| Jardiance | Empagliflozin | 376 | 79 |
| Potassium Chloride | Potassium Chloride | 324 | 81 |
| Furosemide | Furosemide | 306 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 305 | 70 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 259 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 243 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 241 | 63 |
| Simvastatin | Simvastatin | 213 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 208 | 43 |
| Prednisone | Prednisone | 202 | 139 |
| Buspirone Hcl | Buspirone Hcl | 201 | 41 |
| Alprazolam | Alprazolam | 192 | 64 |
| Meloxicam | Meloxicam | 188 | 43 |
| Tramadol Hcl | Tramadol Hcl | 171 | 94 |
| Sertraline Hcl | Sertraline Hcl | 170 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 169 | 54 |
| Eliquis | Apixaban | 168 | 33 |
| Famotidine | Famotidine | 167 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 166 | 42 |
| Doxycycline Hyclate | Doxycycline Hyclate | 164 | 132 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 163 | 49 |
| Ozempic | Semaglutide | 157 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 156 | 28 |
| Trazodone Hcl | Trazodone Hcl | 140 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 136 | 47 |
| Trulicity | Dulaglutide | 121 | 23 |
| Ezetimibe | Ezetimibe | 120 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 115 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 109 | 28 |
| Paroxetine Hcl | Paroxetine Hcl | 108 | 25 |
| Spironolactone | Spironolactone | 108 | 28 |
| Cefuroxime | Cefuroxime Axetil | 104 | 83 |
| Carvedilol | Carvedilol | 100 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 98 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 96 | 31 |
| Cephalexin | Cephalexin | 95 | 75 |
| Warfarin Sodium | Warfarin Sodium | 95 | 17 |
| Azithromycin | Azithromycin | 94 | 64 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 88 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 18 |
| Amoxicillin | Amoxicillin | 81 | 66 |
| Celecoxib | Celecoxib | 81 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 21 |
| Synthroid | Levothyroxine Sodium | 81 | 26 |
| Tradjenta | Linagliptin | 81 | 12 |
| Metformin Hcl Er | Metformin Hcl | 80 | 20 |
| Allopurinol | Allopurinol | 79 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 79 | 20 |
| Lorazepam | Lorazepam | 79 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 71 | 13 |
| Glipizide | Glipizide | 71 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 71 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 69 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 64 | 12 |
| Montelukast Sodium | Montelukast Sodium | 62 | 14 |
| Donepezil Hcl | Donepezil Hcl | 60 | 14 |
| Glimepiride | Glimepiride | 59 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | suppressed |
| Levetiracetam | Levetiracetam | 55 | suppressed |
| Bupropion Xl | Bupropion Hcl | 53 | suppressed |
| Finasteride | Finasteride | 53 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 53 | 17 |
| Glipizide Er | Glipizide | 51 | 11 |
| Xarelto | Rivaroxaban | 51 | suppressed |
| Sucralfate | Sucralfate | 50 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 50 | 13 |
| Januvia | Sitagliptin Phosphate | 49 | suppressed |
| Ondansetron Odt | Ondansetron | 48 | 28 |
| Dexlansoprazole Dr | Dexlansoprazole | 47 | suppressed |
| Nystatin | Nystatin | 47 | 20 |
| Clonazepam | Clonazepam | 46 | 14 |
| Mirtazapine | Mirtazapine | 46 | 11 |
| Novolog Flexpen | Insulin Aspart | 46 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 16 |
| Farxiga | Dapagliflozin Propanediol | 43 | suppressed |
| Pregabalin | Pregabalin | 43 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 39 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Baclofen | Baclofen | 34 | suppressed |
| Bumetanide | Bumetanide | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | suppressed |
| Ibuprofen | Ibuprofen | 31 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Invokana | Canagliflozin | 29 | suppressed |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 28 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 17 |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 22 | 22 |
| Irbesartan | Irbesartan | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 19 | 12 |
| Colestipol Hcl | Colestipol Hcl | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Nyamyc | Nystatin | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 17 |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Tobramycin | Tobramycin | 18 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 14 |
| Valacyclovir | Valacyclovir Hcl | 17 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 14 |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 14 | 13 |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Zafirlukast | Zafirlukast | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Desloratadine | Desloratadine | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Toprol Xl | Metoprolol Succinate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Victoza 3-Pak | Liraglutide | 13 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Enbrel Sureclick | Etanercept | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Glyburide Micronized | Glyburide,micronized | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $221.64 · 6 records | Novo Nordisk Inc | DALVANCE, ELIQUIS, Ozempic, Symbravo, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error